BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20250328
DTSTAMP:20260429T180106
CREATED:20250303T114445Z
LAST-MODIFIED:20250317T083038Z
UID:34229-1742947200-1743119999@senzagen.com
SUMMARY:6th Annual BTEL Summit & Exhibition
DESCRIPTION:Meet us at the 6th Annual BTEL Summit & Exhibition in Berlin. \nOral presentation | 26 March \nBuilding confidence in New Approach Methodologies (NAMs) for biological safety testing of Medical Devices: a successful case study on skin sensitization testing using GARD®  \nAndy Forreryd\, PhD\nScientific Liaison Manager\, SenzaGen
URL:https://senzagen.com/event/btel2025/
LOCATION:Berlin\, Germany
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025BTEL-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250316T080000
DTEND;TZID=Europe/Stockholm:20250320T170000
DTSTAMP:20260429T180106
CREATED:20250207T084353Z
LAST-MODIFIED:20250312T122014Z
UID:34052-1742112000-1742490000@senzagen.com
SUMMARY:2025 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #637 \nOrange County Convention Center\,  Orlando\, FL. \nMeet us and discover how the GARD® assays are transforming skin sensitization testing. Learn about their role in filling data gaps for in vitro skin sensitizing hazard and quantitative potency assessment\, providing a high-performing and ethical alternative to animal testing. \nExhibitor-Hosted Session\nAdvancing NAMs for Skin Sensitization Testing: Potency\, Challenging Substances and Medical Devices \nW208B | Tuesday\, 18 Mar | 10:45 am-11:45 am \n \n  \nBring your questions and testing challenges!\n \nJoin us for an interactive session that combines essential regulatory updates\, case studies\, and a live Q&A! Gain exclusive insights on the latest GARD®data from SenzaGen’s research and industry collaborations\, including key advancements in testing challenging substances\, medical devices\, and quantitative potency assessment. We will also share user cases from industry leaders like dōTERRA\, Clarins\, and Bic Skin Creative. \nOur experts will be available to discuss how GARD® innovations can address your needs and advance your work in skin sensitization testing. \nKey Topics \n\nNew GARD® data from industry collaborations on Natural Extracts and Quantitative Potency Assessment.\nRegulatory update WG8 ISO TC194: Medical Devices ISO 10993-10.\nUser Cases from dōTERRA\, Clarins\, Bic Skin Creative\, and more.\n\nSpeakers \n\nRon Brown\, Toxicologist at Risk Science Consortium (former FDA reviewer for Medical Devices)\nJoe Dawson\, Product Safety Manager at doTERRA International\nAndy Forreryd\, Scientific Liaison\, SenzaGen\n\nPosters\n🎫 G367 | Skin Sensitization Potency GHS/CLP Classification \nMarch 17\, 1:45 pm -4:15 pm | #3242 Subcategorization of skin sensitizers into UN GHS categories using GARD®skin Dose-Response \n🎫 D217 | Medical Devices Testing ISO 10993-10 \nMarch 19\, 9:15 am -11:45 am | #4382 Pre-validation Results from GARD®skin for Medical Devices: In Vitro Sensitization Testing of Medical Device Extracts for Implementation in ISO 10993-10 \n🎫 LB352 | NAMs in Occupational Health – Joint poster with Lundbeck \nMarch 20\, 8:30 am -11:30 am | #5251 Assessing skin sensitizing hazard of Drug Products and Active Pharmaceutical Ingredients using GARD®: New Approach Methodology in Occupational Health and Safety \n🎫 F310 |  Application for Pharmaceuticals – Joint poster presented by SafeBridge \nMar 18\, 1:45 pm-4 pm | #3838 Comparison of β-lactam ring containing substances gene expression signatures related to therapeutic mechanism and the Adverse Outcome Pathway (AOP) for sensitization \n 
URL:https://senzagen.com/event/2025sot/
LOCATION:Orlando\, Fl\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/02/2025-SOT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241031
DTSTAMP:20260429T180106
CREATED:20240905T122507Z
LAST-MODIFIED:20250317T085918Z
UID:33088-1730073600-1730332799@senzagen.com
SUMMARY:ASCCT 13th Annual Meeting
DESCRIPTION:Meet us at the American Society for Cellular and Computational Toxicology (ASCCT) Annual Meeting in Research Triangle Park\, North Carolina. \n  \nOral presentation | Monday\, 28 October | 17:20-17:35\nNAMs for botanical safety evaluation: Case Study on Determine the Safe Use Levels of Genipa Plant Extract in Temporary Tattoo Ink with GARD®\n  \nPoster\nGARD®skin Dose-Response for skin sensitizing potency assessment: Performance on the Reference Chemical Potency List (RCPL)
URL:https://senzagen.com/event/ascct-13th-annual-meeting/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/24050-RAD-ASCCT-13th-Annual-Meeting-Graphics-1584x39676_Page_1-scaled-e1725539063290.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240908T080000
DTEND;TZID=Europe/Stockholm:20240911T170000
DTSTAMP:20260429T180106
CREATED:20240126T092505Z
LAST-MODIFIED:20240905T105818Z
UID:31912-1725782400-1726074000@senzagen.com
SUMMARY:Eurotox 2024
DESCRIPTION:Meet us at Booth #56\nCome meet us at booth #56 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps in skin sensitizing hazard and quantitative potency assessment. Additionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \n  \n \nIndustry-Hosted Session\n“Advancing NAMs for Skin Sensitization” \nGuest speakers from Lundbeck and Unilever\n \nPosters\nSpotlight on Hydrophobic Esters\, PoD\, Defined Approaches\, and more\n🎫 P01-79 #996 | Joint poster with Cargill\nThe applicability of GARD®skin for assessing skin sensitization potential of hydrophobic esters during product development \n🎫 P19-57 #661 | Joint poster with L’Oréal\nImproved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 P19-75 #840 | Joint poster with Sonova\nIntegrating NAMs into early-stage screening of novel materials intended for use in Medical Devices: Case studies on the use of GARD® for in vitro skin sensitization assessment \n🎫 P20-17 #613 | SenzaGen poster\nGARD®skin as a drop-in replacement KE3-method in OECD GD 497 Defined Approaches \n🎫 P23-21 #937 | ToxHub poster\nWorkflow for Occupational Exposure Limit Determination and Banding: Focus on Skin and Respiratory Sensitization using NAMs approaches \n🎫 LP-28 | ToxHub poster\nRisk Assessment Approaches for Nanomaterials in Medical Devices \n 
URL:https://senzagen.com/event/eurotox2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/Lime-banner-new-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240603T080000
DTEND;TZID=Europe/Stockholm:20240606T170000
DTSTAMP:20260429T180106
CREATED:20240126T091543Z
LAST-MODIFIED:20240521T140249Z
UID:31906-1717401600-1717693200@senzagen.com
SUMMARY:ESTIV Congress 2024
DESCRIPTION:Come meet us at booth #22 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment.  \nAdditionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \nPresentations and Posters\nOur team will showcase several posters and presentations. Dive into new scientific data and discover exciting projects done in collaboration with industry partners. \nTuesday 09:00-10:30 | Presentation in Session 2b\nProject in collaboration with L’Oreal. “Improved confidence of quantitative sensitizing potency assessment for PoD using GARD®skin Dose-Response”\n\nThursday 11:30-12:45 | Presentation in Session 9a\n“Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment” \nPoster | Presented by ToxHub\n#334 | “Integrated Risk Assessment and Compliance Strategies for Nanomaterials in Medical Devices”
URL:https://senzagen.com/event/estiv-congress-2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/ESTIV-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240310T080000
DTEND;TZID=Europe/Stockholm:20240314T170000
DTSTAMP:20260429T180106
CREATED:20231115T134814Z
LAST-MODIFIED:20240306T094116Z
UID:31573-1710057600-1710435600@senzagen.com
SUMMARY:2024 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #732\nDiscuss your testing needs with us\n  \nExhibitor-Hosted Session\nExpert round table on NAMs and industry trends\nTuesday\, 12 Mar | 9:00 am-10:00 am\n \n \nPosters\nSpotlight on PoD\, NESILs\, product development and CE-marking of Medical Devices\nMonday\, 11 Mar | 9:15 am-11:15 am\n🎫 Joint poster with Sonova\nP487 #3362 | Unveiling skin sensitizing potential: case studies on biocompatible material development utilizing the in vitro GARD®skin Medical Device assay \n🎫 Joint poster with Duearity\nP480 #3355 | Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment \n🎫 Joint poster presented by RIFM\nP318 #3205 | Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARD®skin Dose-Response assay \nTuesday\, 12 Mar | 2:15 pm-4:15 pm\n🎫 Joint poster with L’Oréal\nP739 #4190 | Improved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 Joint poster presented by IFF\nP762 #4213 | A Next Generation Risk Assessment (NGRA) Framework to conduct Quantitative Risk Assessment (QRA2) to determine safe use levels of fragrance ingredients in cosmetic products \n🎫 Joint poster presented by Inotiv\nP738 #4189 | Testing of Regulatory-Relevant Chemicals for Skin and Respiratory Sensitization Hazard \n\n 
URL:https://senzagen.com/event/sot-annual-meeting-2024-toxexpo/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/11/SOT2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20260429T180106
CREATED:20230824T070701Z
LAST-MODIFIED:20231109T141151Z
UID:30935-1699747200-1700092799@senzagen.com
SUMMARY:ACT 2023 Annual Meeting
DESCRIPTION:→ Booth #333\nSpotlight on difficult-to-test samples and in vitro quantitative potency assessment as an alternative to the Local Lymph Node Assay\nCome meet us at booth #333 and join our poster presentation to learn how the GARD assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment\, providing a high performing and ethical alternative to animal testing. \n→ Joint poster with Takasago\nQuantitative potency assessment of skin sensitizers when developing novel fragrance ingredients\nPractical application of the GARDskin Dose-Response assay to derive a No Expected Sensitization Induction Level (NESIL) value for confirmatory human patch studies to determine safe use level for novel fragrance ingredients \n→ Hot topic\nIn vitro tests supporting Occupational Health\nOccupational allergic dermatitis and asthma are common workplace diseases. By using the in vitro GARD® assays to test for skin and respiratory sensitizers in combination\, it is possible to identify allergens in the work environment and take preventive action. \nCome by our booth to learn more! \n→ Discuss your toxicological risk assessment needs with us!\nMeet our in vitro experts\, Dr Andy Forreryd and Dr Tim Lindberg
URL:https://senzagen.com/event/act-2023-annual-meeting/
LOCATION:Orlando\, Florida\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/banner_ACT2023-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230910T080000
DTEND;TZID=Europe/Stockholm:20230923T170000
DTSTAMP:20260429T180106
CREATED:20230313T144734Z
LAST-MODIFIED:20230831T110511Z
UID:30473-1694332800-1695488400@senzagen.com
SUMMARY:Eurotox 2023
DESCRIPTION:New opportunities for skin sensitization testing with GARD®skin OECD TG 442E\nCome meet us at booth #36 and join our poster presentations to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development.\nMeet also ToxHub\, our latest addition to the Group\, and benefit from expert Toxicology and Regulatory advice.\nBooth #36\n\nDiscuss your toxicological risk assessment needs with us!\n\n \n \nPosters\n\nSpotlight on Difficult-to-Test\, Quantitative Potency\, Medical Devices and E&L Assessment\n\n→ Joint poster with Exxon Mobil\nP07-02 | Assessing the utility of the Genomic Allergen Rapid Detection (GARD®skin) assay to detect dermal sensitization potential in UVCBs and formulated lubricant products \n→ Joint poster with IFF and RIFM\nP22-43 | The GARD® skin Dose-Response assay for determination of a point-of-departure (PoD) for Next Generation Risk Assessment (NGRA) of skin sensitizers: A case study using isocyclocitral \n→ Joint poster with Duearity\nP22-30 | Regulatory approval of medical devices according to MDR using in vitro data from GARD® skin Medical Device for skin sensitization assessment \n→ ToxHub poster\nLP-38 | Toxicological risk assessment of extractable and leachable compounds: mitigating risks in pharmaceutical applications \nNew\n\nTailored Toxicology Services\n\nAt our booth\, you will also meet our independent consultancy unit Toxhub\, specialized in toxicological risk assessment and regulatory strategy consulting\, with expertise in pharmaceuticals\, chemicals\, medical devices and cosmetics. \nExplore ToxHub’s services \n 
URL:https://senzagen.com/event/eurotox-congress-2023/
LOCATION:Ljubljana\, Slovenia\, Slovenia
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/03/Eurotox23v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230831T080000
DTEND;TZID=Europe/Stockholm:20230904T170000
DTSTAMP:20260429T180106
CREATED:20230313T144259Z
LAST-MODIFIED:20230831T105454Z
UID:30467-1693468800-1693846800@senzagen.com
SUMMARY:WC12
DESCRIPTION:12th World Congress on Alternatives and Animal Use in the Life Sciences\nOur team and partners will feature the GARD® assays in several posters and presentations. Join us to explore new scientific data and exciting projects done in collaboration with industry partners.\nSymposia\n\nSpotlight on Medical Devices\, Complex Samples and Dose-Response\n\nWednesday\, Aug 30\, 11:00 – 12:30\, Session S410\n→ In collaboration with Duearity\n#515 Application of the GARD®skin Medical Device assay for regulatory approval of medical devices according to MDR \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ In collaboration with RIFM and IFF\n#208 In vitro determination of a point of departure for Next Generation Risk Assessment (NGRA) of skin sensitizers: Reproducibility and precision of the GARD®skin Dose-Response assay \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ Presented by Emily N Reinke\, Inotiv-RTP\, in collaboration with NIH and Burleson Research Technologies\n#90 Evaluating Skin Sensitization Hazard of Diverse Chemicals Using GARD®skin \nPosters\n\nSpotlight on Complex Mixtures\, Metals and Protein Allergens\n\nTuesday\, Aug 29\, 12:30 – 14:00\n→ Joint poster with Corteva Agriscience\nA33 #230 | GARD®: a study to investigate the applicability domain for agrochemical formulations \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Johnson Matthey\nF81 #55 | Expanding the applicability domain of NAMs for skin sensitization testing: a case study using GARD®skin for assessment of metals \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Merck\nF80 #498 | Characterization of respiratory sensitizing properties of the protein Subtilisin\, using GARD®air \nMeet our team\n\nMeet and greet with Andy Forreryd
URL:https://senzagen.com/event/12th-world-congress-on-alternatives-and-animal-use-in-the-life-sciences-wc12/
LOCATION:Niagara Falls\, Canada\, Niagara Falls\, Canada
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Number-logo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230322T080000
DTEND;TZID=Europe/Stockholm:20230323T170000
DTSTAMP:20260429T180106
CREATED:20221109T100611Z
LAST-MODIFIED:20230322T130845Z
UID:30088-1679472000-1679590800@senzagen.com
SUMMARY:2023 SOT Annual Meeting & ToxExpo
DESCRIPTION:Meet us at this year’s SOT\nCome meet us at our booth and join our hosted session to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development. \n \n  \n  \n\nExhibitor-Hosted Session\n\n\n  \n  \n\nPosters\n\n🎫 P117 |  Joint poster with ExxonMobil Biomedical Sciences\n#3016: Mar 20\, 9:00am-10:45am: Assessing the Utility of the Genomic Allergen Rapid Detection (GARDskin) Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products \n🎫 P329 | Joint poster with Research Institute for Fragrance Materials (RIFM)\n#4456: Mar 22\, 10:45am-12:30pm: GARDskin Dose-Response for Photosensitization: Assessment of Reference Photoirritants and Photoallergens \n🎫 P293 | Poster on Medical Device\n#4422: Mar 22\, 10:45am-12:30pm: In Vitro Assays for Assessment of Skin Sensitization Hazard and Potency of Isobornyl Acrylate \n🎫 P151 | Joint poster with International Flavors & Fragrances Inc. (IFF) and Research Institute for Fragrance Materials (RIFM)\n#5050: Mar 23\, 8:30am-11:30am: Gardskin Dose-Response Assay for Pod Determination of Fragrance Materials and Its Application in Conducting Quantitative Risk Assessment (QRA) \n\nExpanded toxicology testing services\n\nAt our booth\, we will introduce you to how you can use in vitro methods for the biological evaluation of medical devices and how we can support you with tailored toxicology advisory services. We will also present our expanded services for in vitro regulatory toxicity testing. \nFind out about our expanded services and expertise\n 
URL:https://senzagen.com/event/2023-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/Newsletter-banner-SOT.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230215
DTEND;VALUE=DATE:20230218
DTSTAMP:20260429T180106
CREATED:20230111T132555Z
LAST-MODIFIED:20230111T154919Z
UID:30279-1676419200-1676678399@senzagen.com
SUMMARY:PCHi 2023 Expo & SHSOT Forum
DESCRIPTION:Personal Care and Homecare Ingredients 2023 Expo & Shanghai Society of Toxicology Forum\n15-17 February 2023 @The China Import and Export Fair Complex\, Guangzhou\, China\nRead More
URL:https://senzagen.com/event/pchi-2023-expo-shsot-forum/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/msg98-1-2022-07-21-5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260429T180106
CREATED:20221021T092257Z
LAST-MODIFIED:20221128T115912Z
UID:29974-1669852800-1670025599@senzagen.com
SUMMARY:2022 Aromadays
DESCRIPTION:Dec 1-2 | Avignon\, Palais des Papes\, France\nMeet us at the 2022 Aromadays conference in Avignon and talk to our specialists regarding the application of the GARD assays for essential oils. \nScientific session\n09:45 CET\, Dec 2\, 2022\nAre there limitations to the applicability of toxicological tests to essential oils ? Focus on the GARD®skin test\nExiste-t-il des limites à l’application des tests toxicologiques aux Huiles Essentielles? Focus sur le test GARD®skin\nCristina ONCINS PALLAS\, Chargée de l’évaluation toxicologique des ingrédients – CONSORTIUM HE\nDr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen\nRead more here
URL:https://senzagen.com/event/2022-aromadays/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/10/logo_aromadays.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221124T080000
DTEND;TZID=Europe/Stockholm:20221125T170000
DTSTAMP:20260429T180106
CREATED:20221102T083023Z
LAST-MODIFIED:20221121T123857Z
UID:30037-1669276800-1669395600@senzagen.com
SUMMARY:2022 SFT
DESCRIPTION:Nov 24-25 | Avignon\, France\nMeet us at the 2022 annual meeting of the French Society of Toxicology in Avignon and talk to our skin sensitization experts regarding the new opportunities the GARD assays have brought to the field. \nWe will also present a poster: “Quantitative sensitizing potency assessment using GARD®skin Dose-Response”. \nPresented by: Dr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen
URL:https://senzagen.com/event/2022-sft/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/logo_sft.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221121
DTEND;VALUE=DATE:20221126
DTSTAMP:20260429T180106
CREATED:20220825T140904Z
LAST-MODIFIED:20221114T140547Z
UID:29773-1668988800-1669420799@senzagen.com
SUMMARY:2022 ESTIV
DESCRIPTION:Booth#5 | Nov 21-25 | Sitges (Barcelona)\, Spain\nAre you attending the 2022 ESTIV International Congress? Come meet us at our booth and join our scientific sessions to hear the latest news about GARD and how the assays are used for skin sensitization testing. We will also introduce you to our expanded services for in vitro regulatory toxicity testing and how you can use in vitro methods for the biological evaluation of medical devices. \n\nScientific presentations\n\n“In vitro assessment of skin sensitizing potential of process-related impurities in polymeric materials during product development”\nSpeaker:  Dr Andy Forreryd @SenzaGen \nTuesday\, November 22nd\, 2022\, 11:00-13:00 | Session 3a. Models\, biomarkers and assays for systemic and immune toxicity \n“Biocompatibility of medical devices: eye irritation of preserved and unpreserved eye drops on HCE model”\nSpeaker:  Dr Laura Ceriotti @VitroScreen \nThursday\, November 24th\, 2022\, 11:00-12:40| Session 8a – In vitro methods for safety assessment of medical devices \n\n\nPosters\n\n\nJoint poster with Sonova: #307 – “In vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices”\nPoster presentation by Dr Rose-Marie Jenvert @SenzaGen \nSession 8a. In vitro methods for safety assessment of medical devices \nJoint poster with Coty: #275 – “Effect of a modulator on the skin sensitization potency of cosmetic fragrance formulations”\nPoster presentation by Dr Carine Linossier @Coty \nSession 4b. Local toxicity testing (safety and efficacy) \n  \n 
URL:https://senzagen.com/event/2022-estiv/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/ESTIV_Screenshot-2022-08-25.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221019
DTEND;VALUE=DATE:20221022
DTSTAMP:20260429T180106
CREATED:20220825T135715Z
LAST-MODIFIED:20220825T135806Z
UID:29760-1666137600-1666396799@senzagen.com
SUMMARY:2022 ASCCT
DESCRIPTION:Oct 19-21 | Chapel Hill\, N.C.\,USA\nMore information coming soon!
URL:https://senzagen.com/event/2022-ascct/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/22179-RAD-ASCCT-11th-Annual-Meeting-Graphics-Banner-CROPPED-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221007
DTSTAMP:20260429T180106
CREATED:20220707T081238Z
LAST-MODIFIED:20220926T135947Z
UID:29631-1664928000-1665100799@senzagen.com
SUMMARY:2022 Biocompatibility Matters
DESCRIPTION:Oct 5-6 | Copenhagen\, Denmark\nMeet SenzaGen at 2022 Biocompatibility Matters\, a two-day conference in Copenhagen. SenzaGen’s Medical Device specialist and ISO expert Dr Rose-Marie Jenvert will speak on the topic “New approaches to in vitro sensitization – regulatory acceptance”. \n\nKey takeaways:\n\n* An introduction to in vitro assays for skin sensitization\, ISO 10993-10\n* The potential to use polar and non-polar extracts in in vitro assays\n* How in vitro assays can gain regulatory acceptance\n* Case studies on in vitro skin sensitization assessment of medical devices \n\nRead more and register\n\n 
URL:https://senzagen.com/event/2022-biocompatibility-matters/
LOCATION:Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/07/BM-logo@2x-e1622186428171.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220922
DTSTAMP:20260429T180106
CREATED:20220427T123124Z
LAST-MODIFIED:20220916T085253Z
UID:29390-1663718400-1663804799@senzagen.com
SUMMARY:2022 ICT/IUTOX/EUROTOX
DESCRIPTION:2022 International Congress of Toxicology – “Uniting in Toxicology”\n\nDiscussions at this year’s ICT\nNew opportunities for skin sensitization testing with GARDskin OECD TG 442E\n\nCome visit us at our booth and join our industry symposium to learn how the high performance and broad applicability of the GARDskin method bring new opportunities to the field of in vitro skin sensitization testing. We will provide user cases to show how GARD can be used to fill data gaps during regulatory testing and R&D. \n\nIndustry symposium\nNew GARD data on “difficult-to-test” substances and potency assessment\n\nSep 20\, 12:00-13:00 CEST @Room 0.09 Athens\n \nREGISTER HERE TO SECURE YOUR SEAT\n(click the link or fill out the form below)\nFill out my online form.\n \n\nHighlights at our booth #34\nDiscover our expanded in vitro toxicity testing services\n\nDo you have “difficult-to-test” samples or are you looking for quantitative skin sensitizing potency information? Come discuss your testing needs with us and learn more about GARD and our expanded in vitro toxicity testing services for cosmetics\, chemicals and medical devices. \nFIND OUT ABOUT OUR SERVICES AND EXPERTISE
URL:https://senzagen.com/event/2022-ict-iutox-eurotox/
LOCATION:Maastricht
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/04/LIME-banner-v7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220914T143000
DTEND;TZID=Europe/Stockholm:20220914T180000
DTSTAMP:20260429T180106
CREATED:20220825T134032Z
LAST-MODIFIED:20220826T062417Z
UID:29741-1663165800-1663178400@senzagen.com
SUMMARY:2022 MVA MedTech Network meeting
DESCRIPTION:Drug device combination products and substance-based medical devices\nSep 14 | Copenhagen\, Denmark\nMedicon Valley Alliance\, together with member company Innokas Medical\, have the pleasure to invite you to the Medicon Valley Alliance MedTech Network meeting\, on the 14th of September\, focusing on drug-device combination products and substance-based medical devices. \n\nSign up here\n\nThe market for drug-device combination products is growing and it is anticipated that up to one in three medical products in development is a combination of a drug/substance and a MedTech product. Drivers for the growth in combination products is the rise of patients suffering from chronic diseases such as diabetes\, cancer\, and respiratory problems as well as growth in the home-based health care market and technological advancements. \nWhen searching for the correct regulatory approval in the EU the primary mode of action (PMOA) will define the regulatory path for your products. For example\, if the action of your medicinal substance is ancillary\, then your product is regulated as a medical device under MDR\, on the other hand\, if the product is mainly of the medicinal substance the product will be regulated as a medicinal product.  A substance with a therapeutic effect can be either a medicinal product/drug or a medical device\, depending on its primary mechanism of action. \nDeveloping this type of products is associated with a high level of complexity. For combination products\, you need to navigate two of the most intensely regulated pathways in one go: for pharmaceuticals and medical devices. The re-classification of substance-based medical devices according to MDR means a more extensive risk assessment involving scientific evidence of PMOA. \nIn this MVA MedTech Network meeting\, we would like to invite you to hear from experts in the area of developing drug-device combination products and substance-based medical devices as well as hearing from companies sharing their experiences\, challenges and solutions.\nIf you are interested in sharing your company’s approach and experiences with drug-device combination products and/or substance-based medical devices and to speak at the meeting on the 14th of September\, please reach out to Sofia Norås\, sn@mva.org. \nAgenda\n14.30 – 15.00  Registration\, networking and light refreshments\n15.00 – 15.10  Welcome\, Anette Steenberg\, CEO\, Medicon Valley Alliance; Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.10 – 15.15  IP and patents in combination products\, Pernille Winding Gojkovic\, CEO\, Høiberg European Patent Attorneys\n15.15 – 15.45  Challenging development with combination products\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.45 – 16.05  Substance-based medical devices\, Rose-Marie Jenvert\, Product Manager GARD applications SenzaGen\n16.05 – 16.40  Company cases TBC\n16.40 – 17.00  Concluding remarks: Building collaborations between organisations & Q&A to all speakers\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n17.00 – 18.00  Networking
URL:https://senzagen.com/event/2022-mva-medtech-network-meeting/
LOCATION:Medicon Valley Alliance\, Auditorium\, Arne Jacobsens Alle 15 \, 2300 Ørestad City\, Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/220914-medtech-network-banner-1080.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260429T180106
CREATED:20220224T104229Z
LAST-MODIFIED:20220224T105153Z
UID:28967-1649116800-1649375999@senzagen.com
SUMMARY:in-cosmetics Global
DESCRIPTION:The leading global event for personal care ingredients\nApril 5-7 | Porte de Versailles\, Paris | Booth: P102\nMeet SenzaGen and partners PKDERM\, GenEvolutioN\, WatchFrog and CEHTRA at in-cosmetics Global in Paris to find out about our latest innovations for safety and efficacy evaluation of cosmetics and ingredients!
URL:https://senzagen.com/event/in-cosmetics-global-2/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/02/Incosmeticsglobal-2022_1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220327
DTEND;VALUE=DATE:20220401
DTSTAMP:20260429T180106
CREATED:20211209T133110Z
LAST-MODIFIED:20220321T111837Z
UID:28283-1648339200-1648771199@senzagen.com
SUMMARY:2022 SOT
DESCRIPTION:Meet us at the 2022 SOT Annual Meeting & ToxExpo\nBooth #1207 @ San Diego Convention Center\, San Diego\, USA\nAre you attending the 2021 Society of Toxicology Annual Meeting? Come join our hosted session and poster presentations to hear the latest news about GARD™ and how the assays are used for skin sensitization testing. We will also introduce you to how you can use in vitro methods for the biological evaluation of medical devices.  \n\nExhibitor hosted session\n\nMar 29\, 10:30-11:30 EDT\, Room 23A\nNew GARD® data on agrochemical formulations\, fragrance materials\, medical devices and metals:\nTogether with guest speakers from Takasago and Sonova\, our Scientific Liaison Dr Andy Forreryd will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. \n  \n \nBook mark the session in SOT’s event calendar: \nSkin Sensitization: Using In Vitro Tools for Quantitative Potency Assessment as an Alternative to the Local Lymph Node Assay \n  \n\nPosters\n\nLive poster sessions on Mar 28\, 9:00-10:45 EDT\n🎫 P460 | Applicability domain of GARDskin\nThe GARDskin assay: Investigation of the applicability domain of indirectly acting haptens  \n🎫 P850 | Joint poster with Sonova\nIn vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices  \n🎫 P846 | Joint poster with Risk Science Consortium\nAbility of the GARD assay to replace the GPMT and the LLNA for assessment of the skin sensitization potential of medical devices  \n 
URL:https://senzagen.com/event/2022-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2021/12/SOT-2022_small-narrow-green.png
END:VEVENT
END:VCALENDAR